STOCK TITAN

Zenas BioPharma (ZBIO) Financials

ZBIO NASDAQ
FY2025 annual
Revenue $10.0M +100.0% YoY
Net Income -$377.7M n/m YoY
EPS (Diluted) -$8.44 YoY not available
Free Cash Flow -$172.4M n/m YoY
Market Cap $1.8B as of Nov 18, 2026
Price / Sales 179x on $10.0M revenue, FY2025
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 8.4x on $212.3M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 18, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ZBIO SEC filings page.

Zenas BioPharma, Inc. (ZBIO) reported $10.0M in revenue for fiscal year 2025, up 100.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ZBIO FY2025

ZBIO is funding a development-stage cost base externally: revenue remains small while research spending and operating cash needs expand.

External financing exceeded operating cash use in FY2024, with financing of $413M versus operating cash flow of -$120M. In FY2025, financing fell to $215M while operating cash flow reached -$172M, showing that outside funding remained central as internal cash needs approached the financing inflow.

Revenue doubled from $5M in FY2024 to $10M in FY2025, but research and development reached $168M, or 1680.6% of revenue. R&D also increased 20.8%, so the higher revenue base has not yet changed the company’s development-stage cost structure.

Cash consumption is primarily operating rather than physical expansion: FY2025 operating cash flow was -$172M and free cash flow was -$172M. Capital expenditures were only $18K, indicating that the reported cash requirement is being driven mainly by ongoing operating and research expenses, not equipment investment.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 37 / 100
Financial Health Score 37/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Zenas BioPharma, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
54

Zenas BioPharma, Inc. held $360.5M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $172.3M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Zenas BioPharma, Inc. scores 54/100 among other emerging companies.

Dilution
4

Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. Zenas BioPharma, Inc. scores 4/100 on it among other emerging companies.

R&D Intensity
72

Zenas BioPharma, Inc. spent $168.1M on research and development in fiscal year 2025, which was 42.8% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Zenas BioPharma, Inc. scores 72/100 among other emerging companies.

Revenue Progress
4

Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Zenas BioPharma, Inc. scores 4/100 on it among other emerging companies.

Burn Trend
6

Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. Zenas BioPharma, Inc. scores 6/100 on it among other emerging companies.

Balance Sheet
79

Zenas BioPharma, Inc.'s cash, cash equivalents and investments came to $360.5M at the end of fiscal year 2025, against $141.5M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Zenas BioPharma, Inc. scores 79/100 among other emerging companies.

Altman Z-Score Grey Zone
2.44

Zenas BioPharma, Inc. scores 2.44, placing it in the grey zone between 1.81 and 2.99. The largest contribution to the score comes from a market capitalization of $1.8B against total liabilities of $141.5M. This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
2/7

Zenas BioPharma, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) passes.

Earnings Quality No Cash Backing
N/A

Zenas BioPharma, Inc. reported a net loss of $377.7M while operations used $172.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Zenas BioPharma, Inc. reported an operating loss of $383.1M against $7.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$10.0M
YoYn/m
QoQ+900.0%

Zenas BioPharma, Inc. generated $10.0M in revenue in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is up 900.0%.

EBITDA
-$103.4M
YoYn/m
QoQn/m

Zenas BioPharma, Inc.'s EBITDA was -$103.4M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$108.9M
YoYn/m
QoQn/m

Zenas BioPharma, Inc. reported a net loss of $108.9M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$1.65
QoQn/m

Zenas BioPharma, Inc. earned -$1.65 per diluted share (EPS) in Q3 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow
-$58.0M
YoYn/m
QoQn/m

Zenas BioPharma, Inc. recorded an outflow of $58.0M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$177.8M
YoY+53.8%
QoQ-9.6%

Zenas BioPharma, Inc. held $177.8M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
68M
QoQ+4.1%

Zenas BioPharma, Inc. had 68M shares outstanding in Q3 2026. Against the prior quarter it is up 4.1%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-51.3%
YoY-25.1pp
QoQ-6.2pp

Zenas BioPharma, Inc.'s quarterly ROE was -51.3% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 25.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 6.2 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending
$58.5M
YoY+70.0%
QoQ-7.1%

Zenas BioPharma, Inc. invested $58.5M in research and development in Q3 2026. This represents an increase of 70.0% from the same quarter a year earlier. Against the prior quarter it is down 7.1%.

Capital Expenditures
$1K
YoYn/m
QoQn/m

Zenas BioPharma, Inc. invested $1K in capex in Q3 2026, funding long-term assets and infrastructure. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Share Buybacks

Not reported for Q3 2026.

ZBIO Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ZBIO quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$10.0Mn/m$1.0Mn/mN/A$0$0n/m$0n/m$10.0MN/A
R&D Expenses$58.5M+70.0%$62.9M+46.2%$60.4M+73.1%$55.7M+13.3%$34.4M+2.6%$43.0M+27.3%$34.9M+54.2%$49.2M
SG&A Expenses$27.4M+108.2%$15.7M+29.7%$16.9M+36.2%$15.6M+36.0%$13.2M+76.8%$12.1M+105.9%$12.4M+151.7%$11.5M
Operating Income-$103.4Mn/m-$107.7Mn/m-$77.3Mn/m-$238.0Mn/m-$52.6Mn/m-$55.2Mn/m-$37.3Mn/m-$55.6M
EBITDA-$103.4Mn/m-$107.7Mn/m-$77.3Mn/mN/A-$52.6Mn/m-$55.2Mn/m-$37.3Mn/mN/A
Interest Expense$2.1M$1.7M$368KN/AN/AN/AN/AN/A
Income Tax$49K$114K+470.0%N/AN/AN/A$20K-$205KN/A
Net Income-$108.9Mn/m-$111.5Mn/m-$81.0Mn/m-$240.4Mn/m-$51.5Mn/m-$52.2Mn/m-$33.6Mn/m-$52.6Mn/m
EPS (Basic)-$1.65-$1.77-$1.46n/m-$5.17-$1.22-$1.25-$0.80N/A
EPS (Diluted)-$1.65-$1.77-$1.46n/m-$5.17-$1.22-$1.25-$0.80N/A
Diluted Shares (Avg)66M63M56M+33.1%N/A42M42M42MN/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

ZBIO Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ZBIO quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'25FilingQ4'2410-K
Total Assets$675.2M+109.7%$701.7M+139.4%$747.7M+124.0%$383.6M+3.7%$322.0M-20.2%$293.1M$333.8M$370.0M+442.6%
Current Assets$603.4M+103.4%$653.8M+134.7%$730.2M+129.8%$351.2M-1.3%$296.6M-24.7%$278.6M$317.8M$355.9M+495.1%
Cash & Equivalents$177.8M+53.8%$196.6M+346.7%$500.2M+154.5%$110.6M-65.4%$115.6M-67.9%$44.0M-76.1%$196.6M+429.0%$319.7M+462.4%
Short-Term Investments$407.5M+132.5%$446.5M+94.8%$217.0M+87.3%$232.6M+649.6%$175.3M+555.1%$229.3Mn/m$115.8Mn/m$31.0Mn/m
Long-Term Investments$61.8M+476.4%$30.8M+1806.0%$1.3M-27.0%$17.3Mn/m$10.7Mn/m$1.6Mn/m$1.8Mn/m$0n/m
Total Liabilities$462.9M+268.6%$454.6M+750.4%$411.9M+732.9%$141.5M+146.0%$125.6M+185.5%$53.5M$49.4M$57.5M-80.4%
Current Liabilities$64.0M+22.2%$65.8M+23.6%$61.2M+24.5%$62.6M+9.4%$52.4M+19.1%$53.2M$49.1M$57.3M+146.3%
Non-Current Liabilities$398.9M+445.1%$388.8M+180725.6%$350.7M+110528.4%$78.8M+36068.3%$73.2Mn/m$215K$317K$218K-99.9%
Long-Term DebtN/AN/AN/A$78.6M$73.0MN/AN/AN/A
Total Equity$212.3M+8.1%$247.1M+3.1%$335.8M+18.1%$242.1M-22.5%$196.4M-45.4%$239.6Mn/m$284.3Mn/m$312.5Mn/m
Retained Earnings-$1.1Bn/m-$957.6Mn/m-$846.1Mn/m-$765.1Mn/m-$524.7Mn/m-$473.2M-$421.0M-$387.4Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.

ZBIO Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ZBIO quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$58.0Mn/m-$57.2Mn/m-$75.2Mn/m-$52.4Mn/m-$41.1Mn/m-$41.7Mn/m-$37.1Mn/m-$38.6Mn/m
Depreciation & Amortization$4K-63.6%$4K-66.7%$6K-73.9%$10K-69.7%$11K-69.4%$12K-65.7%$23K-30.3%$33K+10.0%
Stock-Based Compensation$17.3M+135.5%$8.6M+42.6%$9.2M+70.7%N/A$7.3M+158.0%$6.0M+293.6%$5.4M+468.7%N/A
Capital Expenditures$1Kn/m$0n/m$2K-88.9%$0-100.0%$0n/m$0-100.0%$18K-18.2%$74K
Free Cash Flow-$58.0Mn/m-$57.2Mn/m-$75.2Mn/m-$52.4Mn/m-$41.1Mn/m-$41.7Mn/m-$37.1Mn/m-$38.6M
Investing Cash Flow-$19.2M-148.0%-$287.7Mn/m$31.6Mn/m-$93.4Mn/m$40.0Mn/m-$112.3Mn/m-$86.3Mn/m-$3.7M
Financing Cash Flow$57.2M-21.2%$42.1M+2342.3%$433.5M+437757.6%$140.8M+7500.8%$72.6M-69.0%$1.7M-99.0%$99Kn/m$1.9M+3606.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

ZBIO Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ZBIO quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Margin-1034.1%-10765.9%N/AN/AN/AN/A-373.3%N/A
Net Margin-1089.2%-11145.6%N/AN/AN/AN/A-335.7%N/A
Return on Equity-51.3%-25.1pp-45.1%-23.3pp-24.1%-12.3pp-99.3%-82.5pp-26.2%-15.5pp-21.8%-11.8%-16.8%
Return on Assets-16.1%-0.1pp-15.9%+1.9pp-10.8%-0.8pp-62.7%-48.5pp-16.0%-6.4pp-17.8%-10.1%-14.2%+21.8pp
Current Ratio9.42+3.8x9.93+4.7x11.94+5.5x5.61-0.6x5.66-3.3x5.236.476.21+3.6x
Debt-to-EquityN/AN/AN/A0.320.37N/AN/AN/A
Liabilities-to-Equity2.18+1.5x1.84+1.6x1.23+1.1x0.58+0.4x0.64+0.5x0.220.170.18
Asset Turnover0.010.0x0.000.0xN/A0.000.000.0x0.000.03N/A
FCF Margin-579.9%-5723.7%N/AN/AN/AN/A-370.7%N/A

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Zenas BioPharma, Inc. ZBIO FY2025 $10.0M -$377.7M N/A $1.8B 37/100
Zymeworks Inc. ZYME FY2025 $106.0M -$81.1M -76.6% $1.8B 79/100
Trevi Therapeutics, Inc. TRVI FY2025 N/A -$42.8M N/A $1.9B —
Maze Therapeutics, Inc. MAZE FY2025 N/A -$131.1M N/A $1.7B —
Sarepta Therapeutics, Inc. SRPT FY2025 $2.2B -$713.4M -32.5% $1.6B 42/100
Harmony Biosciences Holdings, Inc. HRMY FY2025 $868.5M $158.7M 18.3% $1.9B 87/100

Frequently Asked Questions

Zenas BioPharma, Inc. (ZBIO) reported $10.0M in total revenue for fiscal year 2025. This represents a 100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Zenas BioPharma, Inc. (ZBIO) revenue grew by 100.0% year-over-year, from $5.0M to $10.0M in fiscal year 2025.

No, Zenas BioPharma, Inc. (ZBIO) reported a net loss of $377.7M in fiscal year 2025.

Zenas BioPharma, Inc. (ZBIO) reported diluted earnings per share of -$8.44 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Zenas BioPharma, Inc. (ZBIO) had EBITDA of -$383.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Zenas BioPharma, Inc. (ZBIO) had $110.6M in cash and equivalents against $78.6M in long-term debt.

Zenas BioPharma, Inc. (ZBIO) has a return on equity of -156.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Zenas BioPharma, Inc. (ZBIO) recorded an outflow of $172.4M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Zenas BioPharma, Inc. (ZBIO) recorded an outflow of $172.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Zenas BioPharma, Inc. (ZBIO) had $383.6M in total assets as of fiscal year 2025, including both current and long-term assets.

Zenas BioPharma, Inc. (ZBIO) invested $18K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Zenas BioPharma, Inc. (ZBIO) invested $168.1M in research and development during fiscal year 2025.

Zenas BioPharma, Inc. (ZBIO) had 57M shares outstanding as of fiscal year 2025.

Zenas BioPharma, Inc. (ZBIO) had a current ratio of 5.61 as of fiscal year 2025, which is generally considered healthy.

Zenas BioPharma, Inc. (ZBIO) had a debt-to-equity ratio of 0.32 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Zenas BioPharma, Inc. (ZBIO) had a liabilities-to-equity ratio of 0.58 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Zenas BioPharma, Inc. (ZBIO) had a return on assets of -98.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Zenas BioPharma, Inc. (ZBIO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $1.8B as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Zenas BioPharma, Inc. (ZBIO) trades at 179x sales, its market capitalization divided by $10.0M revenue, FY2025. The market capitalization is $1.8B as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Zenas BioPharma, Inc. (ZBIO) held $360.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $172.3M over that year. Dividing the one by the other, the reported balance equals about 25 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Zenas BioPharma, Inc. (ZBIO) has an Altman Z-Score of 2.44, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Zenas BioPharma, Inc. (ZBIO) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Zenas BioPharma, Inc. (ZBIO) reported a net loss of $377.7M while operations used $172.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Zenas BioPharma, Inc. (ZBIO) reported an operating loss of $383.1M against $7.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Zenas BioPharma, Inc. (ZBIO) scores 37 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top